Feature Partner
Clairvoyant Therapeutics
Company Summary
Clairvoyant Therapeutics is a Canadian biotechnology company developing a quick-to-market clinical strategy designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.
Clairvoyant is focused on the clinical validation of psilocybin in Canada, E.U. & the U.K. with a primary focus on CLARITY, the company's Phase 2 clinical trial investigating psilocybin in the treatment of alcohol use disorder.